Mathieu Nonnenmacher
Vice President, Gene Therapy Voyager Therapeutics
Mathieu Nonnenmacher is currently leading the Novel Capsid Discovery group at Voyager Therapeutics, a Massachusetts gene therapy company using AAV for treatment of severe neurological diseases including Huntingtons disease, Friedreichs Ataxia and amyotrophic lateral sclerosis. During his postdoctoral training at Mount Sinai School of Medicine, Mathieu identified a natural mechanism of capsid-genome correlation that had important implications for the development of AAV libraries for Directed Evolution. Mathieu Joined Voyager Therapeutics in 2014 to develop capsid engineering for brain delivery. Since then, he established the TRACER biopanning platform which led to the discovery of numerous neurotrophic capsid variants in mouse and non-human primates. The Voyager team has recently discovered the mechanism of action of certain capsids, leading to the developments of novel viral and non-viral shuttles capable of crossing the blood-brain barrier.
Seminars
- Translate ALPL-mediated BBB transport from platform discovery into clinical reality, supported by early human data and safety readouts
- Position ALPL as a differentiated, cross-species BBB target with improved translational relevance beyond legacy approaches such as TfR1
- Demonstrate how strong NHP validation of ALPL-targeting capsids enables progression into clinical CNS programs, including tau knockdown in Alzheimer’s disease
- Showcase next-generation capsid engineering strategies that enhance brain-wide transduction, reduce off-target effects, and improve systemic gene therapy delivery
